Clinical Trial

ReDS-Guided Decongestion in Acute Heart Failure (ReDS-LATAM HF)

Study acronym: ReDS-LATAM HF
Active, Not Recruiting
View on ClinicalTrials.gov →
Summary
Heart failure (HF) is a leading cause of hospitalization, with high rates of early readmission largely driven by residual congestion at discharge. Conventional methods to assess congestion are often imprecise and may fail to guide optimal decongestive therapy. Remote Dielectric Sensing (ReDS) is a non-invasive technology that provides a rapid and objective estimate of lung fluid content. This study aims to evaluate whether a ReDS-guided decongestion strategy improves clinical outcomes compared with standard care in patients hospitalized for acute heart failure. In this randomized controlled trial, patients will be assigned 1:1 to a ReDS-guided strategy or standard care. ReDS measurements will be performed in both groups but will only guide treatment in the intervention arm. The primary endpoint is a composite of all-cause mortality, heart failure rehospitalization, or unplanned HF visit within 30 (±5) days after discharge.
Trial Details
NCT Number NCT07600398
Lead Sponsor Instituto Cardiovascular de Buenos Aires
Conditions Acute Heart Failure (AHF)
Enrollment 216 participants
Start Date 2026-05-01
Primary Completion 2027-06-01 (estimated)
Study Completion 2027-06-01 (estimated)
Updated on ClinicalTrials.gov 2026-05-20